Literature DB >> 3718810

A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.

S L Bowman, S A Hudson, G Simpson, J F Munro, J A Clements.   

Abstract

The pharmacokinetics of intravenous and oral propranolol have been compared in six obese and six normal subjects matched for age and sex. After intravenous administration there was no difference in plasma clearance but the volume of distribution was greater (V = 339 l vs 198 l) and the half-life was longer (t1/2 = 5.0 h vs 3.0 h) in the obese group. No important difference in the rate of oral absorption was observed. A trend towards higher systemic availability in the obese group (35% vs 27%) was not statistically significant.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3718810      PMCID： PMC1401028          DOI： 10.1111/j.1365-2125.1986.tb02837.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  9 in total

1.  Data point weighting in pharmacokinetic analysis: intravenous paracetamol in man.

Authors:  J A Clements; L F Prescott
Journal:  J Pharm Pharmacol       Date:  1976-09       Impact factor: 3.765

2.  Alterations in drug distribution and clearance due to obesity.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1981-06       Impact factor: 4.030

3.  Lidocaine disposition in obesity.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Am J Cardiol       Date:  1984-04-01       Impact factor: 2.778

Review 4.  Clinical pharmacokinetics of propranolol.

Authors:  P A Routledge; D G Shand
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

5.  Direct measurement of propranolol bioavailability during accumulation to steady-state.

Authors:  A J Wood; K Carr; R E Vestal; S Belcher; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

6.  The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; R B Smith; R I Shader
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

7.  Effect of age, gender, and obesity on midazolam kinetics.

Authors:  D J Greenblatt; D R Abernethy; A Locniskar; J S Harmatz; R A Limjuco; R I Shader
Journal:  Anesthesiology       Date:  1984-07       Impact factor: 7.892

Review 8.  Pharmacokinetics of drugs in obesity.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

9.  Theophylline disposition in obesity.

Authors:  P Gal; W J Jusko; A M Yurchak; B A Franklin
Journal:  Clin Pharmacol Ther       Date:  1978-04       Impact factor: 6.875
  9 in total
  14 in total

1.  Determinants of Propranolol's Selective Effect on Loss Aversion.

Authors:  Peter Sokol-Hessner; Sandra F Lackovic; Russell H Tobe; Colin F Camerer; Bennett L Leventhal; Elizabeth A Phelps
Journal:  Psychol Sci       Date:  2015-06-10

Review 2.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

4.  Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers.

Authors:  C Le Jeunne; J M Poirier; G Cheymol; O Ertzbischoff; F Engel; F C Hugues
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

Review 6.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 7.  Challenges to Safe and Effective Pain Management in Patients With Super Obesity: Case Report and Literature Review.

Authors:  Neha M Kramer; Halena M Gazelka; Virginia H Thompson; John A Batsis; Keith M Swetz
Journal:  J Pain Symptom Manage       Date:  2017-11-16       Impact factor: 3.612

Review 8.  The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies.

Authors:  Meysam Zarezadeh; Ahmad Saedisomeolia; Mahoor Shekarabi; Masoud Khorshidi; Mohammad Reza Emami; Daniel J Müller
Journal:  Eur J Nutr       Date:  2020-11-03       Impact factor: 5.614

9.  Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent.

Authors:  Pan Pantziarka; Gauthier Bouche; Vidula Sukhatme; Lydie Meheus; Ilse Rooman; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2016-10-12

10.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.